Does the media prefer ARQT or ELAN?

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 8 mentions for Elanco Animal Health. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Elanco Animal Health's score of 0.17 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ARQT or RDY?

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 2 mentions for Dr. Reddy's Laboratories. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AXSM or ARQT?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Axsome Therapeutics' score of 0.15 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARQT or LNTH?

In the previous week, Arcutis Biotherapeutics had 8 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 2 mentions for Lantheus. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Lantheus' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARQT or BLTE?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 4 mentions for Belite Bio. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Belite Bio's score of 0.39 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Arcutis Biotherapeutics (ARQT) Competitors

$25.48 +0.99 (+4.05%)

As of 10:38 AM Eastern

Compare

ARQT vs. ELAN, RDY, AXSM, LNTH, and BLTE

Should you buy Arcutis Biotherapeutics stock or one of its competitors? Arcutis Biotherapeutics's main competitors and comparable companies include Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Arcutis Biotherapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.19	-$16.14M	$0.21	116.62
Elanco Animal Health	$4.72B	2.38	-$232M	-$0.41	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Elanco Animal Health's net margin of -3.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Elanco Animal Health	-3.96%	8.13%	3.99%

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 8 mentions for Elanco Animal Health. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Elanco Animal Health's score of 0.17 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics currently has a consensus target price of $36.00, suggesting a potential upside of 47.00%. Elanco Animal Health has a consensus target price of $29.70, suggesting a potential upside of 32.03%. Given Arcutis Biotherapeutics' higher possible upside, equities research analysts clearly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Arcutis Biotherapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 2 mentions for Dr. Reddy's Laboratories. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Dr. Reddy's Laboratories has higher revenue and earnings than Arcutis Biotherapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.19	-$16.14M	$0.21	116.62
Dr. Reddy's Laboratories	$3.58B	2.85	$456M	$0.44	27.76

Arcutis Biotherapeutics has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Arcutis Biotherapeutics currently has a consensus price target of $36.00, indicating a potential upside of 47.00%. Dr. Reddy's Laboratories has a consensus price target of $1,450.00, indicating a potential upside of 11,770.65%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Dr. Reddy's Laboratories on 10 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Axsome Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $275.74, suggesting a potential upside of 62.12%. Arcutis Biotherapeutics has a consensus price target of $36.00, suggesting a potential upside of 47.00%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Axsome Therapeutics had 2 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Axsome Therapeutics' score of 0.15 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a net margin of 6.15% compared to Axsome Therapeutics' net margin of -24.68%. Arcutis Biotherapeutics' return on equity of 15.05% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Arcutis Biotherapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	11.47	-$183.17M	-$3.75	N/A
Arcutis Biotherapeutics	$376.07M	8.19	-$16.14M	$0.21	116.62

Summary

Axsome Therapeutics beats Arcutis Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Lantheus?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Lantheus has a net margin of 17.69% compared to Arcutis Biotherapeutics' net margin of 6.15%. Lantheus' return on equity of 28.10% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Lantheus	17.69%	28.10%	14.35%

99.1% of Lantheus shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arcutis Biotherapeutics has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Lantheus has higher revenue and earnings than Arcutis Biotherapeutics. Lantheus is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.84	-$16.14M	$0.21	120.25
Lantheus	$1.54B	4.25	$233.56M	$4.14	24.24

In the previous week, Arcutis Biotherapeutics had 8 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 2 mentions for Lantheus. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Lantheus' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics presently has a consensus price target of $36.00, indicating a potential upside of 42.56%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.72%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Arcutis Biotherapeutics beats Lantheus on 9 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Belite Bio?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

0.5% of Belite Bio shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Belite Bio's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Belite Bio	N/A	-11.84%	-11.62%

Arcutis Biotherapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.84	-$16.14M	$0.21	120.25
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 4 mentions for Belite Bio. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Belite Bio's score of 0.39 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics presently has a consensus price target of $36.00, suggesting a potential upside of 42.56%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 41.26%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Arcutis Biotherapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Arcutis Biotherapeutics beats Belite Bio on 12 of the 15 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.16B	$12.31B	$7.20B	$13.25B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	119.55	797.61	274.62	26.05
Price / Sales	6.84	830.73	580.58	80.96
Price / Cash	N/A	86.17	76.82	53.72
Price / Book	16.29	10.71	11.00	6.30
Net Income	-$16.14M	$2.82B	$3.49B	$381.77M
7 Day Performance	0.37%	-1.08%	-1.17%	-1.30%
1 Month Performance	5.93%	-5.90%	-5.69%	-4.31%
1 Year Performance	21.94%	-5.70%	3.89%	-0.49%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	4.255 of 5 stars	$25.48 +4.0%	$36.00 +41.3%	+15.3%	$3.20B	$463.98M	121.27	354	Analyst Forecast
ELAN Elanco Animal Health	3.8565 of 5 stars	$22.14 -1.0%	$29.70 +34.1%	+10.6%	$11.06B	$4.72B	N/A	9,400	News Coverage
RDY Dr. Reddy's Laboratories	3.9965 of 5 stars	$12.06 -1.8%	$1,450.00 +11,928.2%	-12.8%	$10.05B	$3.58B	27.36	27,527
AXSM Axsome Therapeutics	3.4432 of 5 stars	$168.94 -2.3%	$275.84 +63.3%	+43.3%	$8.85B	$638.50M	N/A	925	Analyst Forecast
LNTH Lantheus	2.5553 of 5 stars	$100.24 +0.1%	$108.11 +7.9%	+87.0%	$6.54B	$1.54B	24.22	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, RDY, AXSM, LNTH, and BLTE

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Lantheus?

Summary

How does Arcutis Biotherapeutics compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, RDY, AXSM, LNTH, and BLTE

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Which has higher earnings & valuation, ARQT or ELAN?

Do insiders & institutionals hold more shares of ARQT or ELAN?

Is ARQT or ELAN more profitable?

Does the media prefer ARQT or ELAN?

Do analysts recommend ARQT or ELAN?

Which has more risk and volatility, ARQT or ELAN?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Does the media prefer ARQT or RDY?

Is ARQT or RDY more profitable?

Which has preferable earnings and valuation, ARQT or RDY?

Which has more volatility and risk, ARQT or RDY?

Do analysts rate ARQT or RDY?

Do institutionals & insiders believe in ARQT or RDY?

Summary

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Which has more risk and volatility, AXSM or ARQT?

Do analysts recommend AXSM or ARQT?

Do institutionals and insiders hold more shares of AXSM or ARQT?

Does the media favor AXSM or ARQT?

Is AXSM or ARQT more profitable?

Which has higher earnings & valuation, AXSM or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Lantheus?

Is ARQT or LNTH more profitable?

Do insiders and institutionals have more ownership in ARQT or LNTH?

Which has more risk and volatility, ARQT or LNTH?

Which has stronger valuation & earnings, ARQT or LNTH?

Does the media refer more to ARQT or LNTH?

Do analysts recommend ARQT or LNTH?

Summary

How does Arcutis Biotherapeutics compare to Belite Bio?

Do insiders and institutionals have more ownership in ARQT or BLTE?

Is ARQT or BLTE more profitable?

Which has more volatility and risk, ARQT or BLTE?

Which has better valuation & earnings, ARQT or BLTE?

Does the media favor ARQT or BLTE?

Do analysts recommend ARQT or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools